ALPHELYS’s patent on a new tissue array construction technology is granted in New-Zeland.

ALPHELYS is granted a new patent by French Patent Office on a new technology for tissue array construction. This innovative technology simplifies, accelerates and makes tissue array automation more reliable. This technology is at the origin of MiniCore® ALPHELYS’ new semi-automated tissue arrayer. The patent should soon be granted by the European Patent Office. The patent is currently in world extension phase.

ALPHELYS and SEROA sign an exclusive agreement by which terms ALPHELYS will develop SEROA reagents business over a large region including numerous European countries and USA . ALPHELYS will also distribute SEROA's products in France in the hospital sector which was historically never prospected by SEROA.

SEROA is a Monaco based company which invented more than 20 years ago a technique called CytoScreen® for monolayer cytology (also called Liquid Based Cytology) analysis of cervix samples within the framework of tracking cervix cancer. CytoScreen® is widely used since many years in the private labs in France and particularly at Laboratoires Pasteur-Cerba, the largest European private lab.

CytoScreen® has proven its efficiency since many years against mostly American competitors. CytoScreen®, only approuved kit using centrifugation in the sample preparation, is in particular recognized for the high quality of the homogenous cells spread on the slide after preparation which is demonstrated to be much more representative than the one obtained with alternative techniques that tend to clean too much the samples and may eliminate cells which can prove important into the diagnosis.

This important agreement for both companies is completed with a distribution agreement of ALPHELYS products by SEROA in private french labs. This includes RCL2®, new alternative, non toxic formol-free solution to formulated fixatives, SnapFrost®, a -80°C liquid nitrogen-free snap-freezing system and imaging software for image capture and archiving.

Beyond these commercial agreements, it is very important long term cooperation that is engaged between ALPHELYS and SEROA during which ALPHELYS will develop, based on its various expertises in instrument design and software development, an integrated solution for liquid base cytology which will propose sample preparation automation and automated image analysis on slide.

SEROA will develop complementarily its scientific expertises to enlarge the spectrum of applications for the CytoScreen® techniques opening new perspectives of markets.

If you want more details, please contact:

Pierre CHAUMAT, President & CEO ALPHELYS, pierre.chaumat@alphelys.com , +33 1 30 07 52 95 or

Yves BORDET, President SEROA, Yves.bordet@seroa.com , +377 93 30 65 40

Eric SALLEN ,  Vice-President SEROA, esallen.seroa@wanadoo.fr, +377 93 30 65 40

ALPHELYS signs an exclusive agreement for the distribution of BRIGHT INSTRUMENTS cryostats and microtomes in France and in French speaking African countries.

The line of BRIGHT INSTRUMENTS cryostats and microtomes perfectly complements an already very dense offer of technologies for histology and pathology labs for an again increased service for our customers.

BRIGHT INSTRUMENTS is a very old english company which based its business on refrigeration expertise. Since the 50ths, BRIGHT INSTRUMENTS proposes to labs a line of cryostats and microtomes of worldwide renown reputation of quality, reliability and durability without equivalent in the world still today. It is indeed not rare to see cryostats sold 25 years before still operating every day in routine lab.

Many innovations that have made cryostats and microtomes technology evolve over time have been invented by BRIGHT INSTRUMENTS and particularly the use of beryllium in mechanical movements that brought an everlasting accuracy, section after section.

With BRIGHT INSTRUMENTS products, ALPHELYS consolidates its position into pathology labs with an always highly demanding offer in quality and performance.

If you want more details, please contact:

Pierre CHAUMAT, President & CEO ALPHELYS, pierre.chaumat@alphelys.com , +33 1 30 07 52 95 or

Alan BRIGHT, President BRIGHT INSTRUMENTS , abright@brightinstruments.com , +44 (0)1480 454528.

ALPHELYS SARL proceeds to a capital increase from 16,000 to 40,000 €uros and to the transformation of its statuts from SARL to SAS.
These operations are defined within a more global strategy of structuration of the company to consolidate a very fast growth (over 45%/year since 4 years), facilitate access to venture capital and push ALPHELYS SAS to a true industrial phase of development to guarantee its durability. This consolidation will also be the opportunity to increase again the quality level of our services to our customers.

BIOGENEX has been for over 20 years a leading company in molecular pathology. BIOGENEX designs and markets a complete range of innovative automates and associated reagents for staining and labelling in immuno-histochimie, ISH and FISH. BIOGENEX is the only company capable to supply a truly complete solution for cell and tissue testing.

Extremely active in Research and Development, BIOGENEX is at the source of numerous worldwide innovations having generated patents like antigen retrieval (1989), deparaffinization without xylene (2003), many technology innovations in slide staining and many complete detection kits, all FDA approved.

ALPHELYS takes on promotion, marketing and technical support of the whole BIOGENEX range of products including autostainers, antigen retrieval systems and reagents lines.

With an already strong presence since many years with its own products and integrated solutions for histo-pathology and molecular pathology that complement well with Biogenex's, and a reknown quality of technical support, ALPHELYS is registered like a strong asset for the development of BIOGENEX in France and intends well to put forward the technical and qualitative arguments products BIOGENEX to gain the significant shares of market.

Jun 10, 2004

ALPHELYS and ADVALYTIX sign an agreement for the exclusive distribution of ADVALYTIX's SlideBooster® IHC and FISH incubator in France.
ADVALYTIX has invented a very innovative and performing technology for the agitation of small volumes during incubation in IHC and FISH staining procedures.
This new technique brings in numerous benefits including strongly reduced quantity of required reagents, strongly reduced incubation duration and much higher contrast of staining for a more reliable and easier diagnostic.
With this new technology, ALPHELYS intend to complete its range of high content products for histology and pathology.

Feb 11, 2001

AMELYS and ARCTURUS Inc, leader of the laser microdissection in the world, signed a long term agreement of commercial partnership for the development of the marketing activities, commercial and support in France, Belgium and Switzerland French-speaking people. Because of the long expertise of AMELYS team in laser microdissection, this agreement also envisages moreover crossed actions for the European development of ARCTURUS.
This agreement corresponds to ARCTURUS new strategy to get closer to the European market with noticeably a direct settlement as ARCTURUS GmbH in Germany which will add its efforts to the already existing subsidiary in UK operating since 4 years now.
This German subsidiary company will become from 2002 the headquarters of ARCTURUS in Europe and will propose in particular a center for training to the techniques of laser microdissection and microgenomic (extraction/purification and amplification of DNAs/RNAs and staining).
A French subsidiary company must also be born in partnership with AMELYS which will ensure the commercial deals and administrative of them. By signing this agreement, ARCTURUS Inc reaffirms its policy of "customer first" and strategy of specialist in microgenomic by choosing a partner who intends to be with the height of these new scientific challenges, technical and commercial thanks to a team which has since the beginning assured the support ARCTURUS in FRANCE.